Decibel Therapeutics Stock Price | DBTX Stock Quote, News, and History
327d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, CPRI, CEQP, ESTE
334d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, VRTV, CTG, DBTX
341d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRTV, CTG, DBTX, CPRI
348d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, DBTX, TRHC
355d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, DBTX, VRTV, ZYNE
- All
- Buy
- Hold
- Sell
| 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Dividend | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - |
| EPS | - | - | - | - |
| P/E Ratio | -1.92 | -2.99 | -4.96 | -70.14 |
| EBIT | - | - | - | - |
| EBITDA | - | - | - | - |
| Net Profit | - | - | - | - |
| Net Profit Adjusted | - | - | - | - |
| Pre-Tax Profit | - | - | - | - |
| Net Profit (Adjusted) | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - |
| EPS (GAAP) | - | - | - | - |
| Gross Income | - | - | - | - |
| Cash Flow from Investing | - | - | - | - |
| Cash Flow from Operations | - | - | - | - |
| Cash Flow from Financing | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - |
| Book Value per Share | - | - | - | - |
| Net Debt | - | - | - | - |
| Research & Development Exp. | - | - | - | - |
| Capital Expenditure | - | - | - | - |
| Selling, General & Admin. Exp. | - | - | - | - |
| Shareholder’s Equity | - | - | - | - |
| Total Assets | - | - | - | - |
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Decibel Therapeutics Inc Registered Shs | 0.00 | 0.00 | USD |
| 2021 | Decibel Therapeutics Inc Registered Shs | 0.00 | 0.00 | USD |
| 2020 | Decibel Therapeutics Inc Registered Shs | - | - | USD |
| 2019 | Decibel Therapeutics Inc Registered Shs | - | - | USD |
| 2018 | Decibel Therapeutics Inc Registered Shs | - | - | USD |
*Yield of the Respective Date
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The firm focuses on hearing disorders, including noise-induced hearing loss, residual hearing preservation or improved sound fidelity with cochlear implants, presbycusis or age-related hearing loss, tinnitus, a persistent ringing in the ears, and genetic hearing loss. It also offers drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded in October 2015 and is headquartered in Boston, MA.
| Owner | in % |
|---|---|
| Freefloat | 91.65 |
| OrbiMed Advisors LLC | 19.68 |
| OrbiMed Advisors Private Equity | 19.68 |
| TRV GP III LLC | 12.50 |
| Regeneron Pharmaceuticals, Inc. | 8.35 |
| Citadel Advisors LLC (13f Subfiler) | 7.04 |
| BlackRock Advisors LLC | 6.92 |
| Alphabet, Inc. | 6.51 |
| BlackRock Health Sciences Opportunities Portfolio | 3.57 |
| Samsara Biocapital LLC | 3.19 |
| Samsara Biocapital LLC | 3.19 |
| BlackRock Health Sciences Trust II | 3.16 |
| Vanguard Group, Inc. (Subfiler) | 2.55 |
| Vanguard Total Stock Market ETF | 1.92 |
| Harvard Management Co., Inc. | 1.30 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLDBra9mq6SksKw%3D